{'fraction_non_alphanumeric': 0.04758364312267658, 'fraction_numerical': 0.025278810408921933, 'mean_word_length': 5.565853658536585, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Bioequivalence evaluation of two brands of gliclazide 80 mg tablets (Glyzide® & Diamicron®) — in healthy human volunteers

A randomized, two‐way, crossover, bioequivalence study in 24 fasting, healthy, male volunteers was conducted to compare two brands of gliclazide 80 mg tablets, Glyzide®(Julphar, UAE) as test and Diamicron® (Servier Industries, France) as reference product. The study was performed at the International Pharmaceutical Research Centre (IPRC), in joint venture with Speciality Hospital, Amman, Jordan. The drug was administered with 240 ml of 20% glucose solution after a 10 h overnight fasting. After dosing, serial blood samples were collected for a period of 48 h. Plasma harvested from blood was analyzed for gliclazide by validated HPLC method. Various pharmacokinetic parameters including AUC0–t, AUC0–∝, Cmax, Tmax, T1/2, and elimination rate constant were determined from plasma concentrations of both formulations. Statistical modules (ANOVA and 90% confidence intervals) were applied to AUC0–t, AUC0–∝, and Cmax for bioequivalence evaluation of the two brands which revealed no significant difference between them, and 90% CI fell within US FDA accepted bioequivalence range of 80–125%. Based on these statistical inferences, Glyzide® was judged bioequivalent to Diamicron®. Copyright © 2002 John Wiley & Sons, Ltd.